INTRODUCTION
NOS isoforms have been identified in malignant tumors where their expression levels correlate with tumor grade. NOS II and NOS III are co-expressed in some human (4) (5) (6) (7) (8) and rodent tumors (9) . Other tumors reportedly express either NOS III (6, 8) or NOS II exclusively (10) . The relative contributions of the different isoforms to the growth of a tumor can be assessed in principle, using synthetic analogues of Larginine that competitively inhibit all three isoforms (11) , together with inhibitors with much greater selectivity for NOS II, such as AG (12, 13) and 1400W (14) .
NO can inhibit or enhance tumor growth (15) , depending on its concentration. Low
[NO]s facilitate blood flow, ensuring the efficient delivery of nutrients and oxygen to the tumor (16) (17) (18) (19) . They also enhance vascular permeability (10, 20) and stimulate angiogenesis, facilitating the development of the tumor neovasculature (21, 22) .
These effects promote tumor growth and assist metastatic spread. However, other studies report that NO can suppress tumor growth (23) , typically following induction of the NOS II isoform. The high [NO] s generated by this enzyme react with oxygenderived radicals to generate highly-reactive nitrogen species (RNS), a condition called 'nitrosative stress'. RNS react with cellular macromolecules (proteins, lipids, nucleic acids), generally with adverse outcomes that can result in cell death, for example, by initiating apoptosis or cell necrosis (24) .
NOS-II has been highlighted as the predominant isoenzyme that facilitates tumor progression (25) , prompting the search for novel therapies based on highly-selective NOS-II inhibitors (26) . However, this strategy can offer only limited therapeutic benefit where constitutive isoforms are the major, or perhaps the only, source of NO (27) . An alternative approach is to 'scavenge' NO before it can exert its effects.
Scavengers will react with NO from all sources and their efficacy will depend upon the rate of reaction with the ligand and the tissue distribution (compartmentalization) of different NOS isoforms. Assuming second order reaction kinetics, scavenging will be most effective in regions where the NO concentration is greatest, reducing NO preferentially in regions of 'inappropriate' overproduction, while having less effect on essential basal NO levels.
NO is a ligand for transition metals, especially ruthenium, where the formation of nitrosyl complexes is a notable feature of its chemistry (28) . Ru(III) readily reacts with NO to form Ru(II) mononitrosyls containing a linear Ru-N-O bond. The Ru-N-O bond is very stable; consequently the nitrosyl moiety is not readily displaced (29). Ru can be chelated with a suitable ligand to confer water solubility and ensure rapid clearance in vivo, while providing an accessible binding site for NO (30 (31) , the nitrosyl-adduct of AMD6221. NO scavenging was also demonstrated in several animal disease models. AMD6245 and AMD6221 reversed the hypotension in rodent (32) and porcine models of endotoxic shock (33) . AMD3689 was identified in the supernatant of activated RAW264 cells (31) and also in the plasma of rats treated with AMD6221 in a model of cardiac allograft rejection (34) , providing clear evidence for NO scavenging as the underlying mechanism of action. AMD6221 also reduced ocular inflammation in a rabbit model of lipopolysaccharide-induced uveitis. Significantly, one study (31) showed that AMD6221 did not alter either the level of expression or catalytic activity of NOS-II.
Here we report on the effects of AMD6245 and AMD6221 on the growth and vascularization of a rat carcinosarcoma P22 (35) . We have compared the results with those obtained using L-NAME, a non-selective NOS inhibitor, and with AG and 1400W, both of which display greater selectivity for NOS-II than for NOS III (13, 14) . The molecular structures of these compounds are shown in Figure 1 .
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MATERIALS AND METHODS
The procedures used throughout complied with the requirements of the Animals (Scientific Procedures) Act 1986 and with the prevailing UKCCR guidelines.
Tumor implants
Male BD-IX rats (10-12 weeks; 300-380g) were used. Animals were age-matched to minimize differences in both the angiogenic response (36) and vascular NOS III expression (37) .
The mixed P22 carcinosarcoma was used for all experiments (35) . Small fragments (ca. 1mm
3 ) from the cortex of a freshly-passaged tumor were implanted subcutaneously on to the dorsum of syngeneic male rats, close to the mid-line (either 2 or 4 per animal; see below). Alternatively, tumor 'slurries' were prepared and injected 
Tumor growth curves
The long (Y) and short (X) axes of each tumor were measured daily or on alternate days using skin-fold calipers. Tumor volumes (V) were estimated using the hemi- 
Effect of NOS inhibitors on tumor growth
Male BD-IX rats were maintained on a normal laboratory diet, supplemented by the addition of L-NAME (1-10 mg/ml), AG (1 mg/ml) or 1400W (1 mg/ml) to the drinking water. Chronic oral administration of these compounds at these doses has been shown to be effective at inhibiting NOS isoforms in several different models (18; and Discussion). The drinking water also contained sucrose (10 mg/ml) to mask the taste of NOS inhibitors. The time at which treatment with NOS inhibitors commenced, relative to the time of implantation, and the duration of each treatment, varied in different experiments. Animals were either treated continuously until sacrificed, or treatment was discontinued and animals were maintained for a further 7 days before sacrifice. Some effects of L-NAME were reversed in the latter experiments and for this reason we refer to this interval as the 'recovery' period.
Control groups of animals were allowed access to water containing sucrose only.
Effect of Ru NO scavengers on tumor growth
Animals used in this study (24 BD-IX rats) received 2 implants. After surgery they were randomly placed into 3 groups of 8 animals (n = 16 tumors/group). efficacy in previous whole animal studies (32, 34) . Three animals in each group were sacrificed on day +28 and the remaining 5 were maintained for a further 7 days without treatment (= recovery period) before sacrifice.
Immunohistochemistry
Cryostat sections (7 μm) of snap-frozen tumors were mounted on poly-L-lysine coated slides, air-dried and fixed in acetone (10 min). Endogenous peroxidase activity was blocked with 0.3 % hydrogen peroxide in 70 % methanol (30 min). Sections were then overlaid with mouse anti-rat CD31/PECAM-1 (Serotec) mab, followed by secondary anti-mouse pre-absorbed labelled-streptavidin-biotin immunoperoxidase antibody. Diaminobenzadine tetrahydrochloride (DAB) was the substrate (LSAB-IP kit, DAKO).
The distribution of NOS II and NOS III isoforms was also studied, using double immunofluorescence. Tumor sections were fixed as above, overlaid with abs to NOS II (Santa Cruz Biotech) or NOS III (Transduction Labs) for 45 min and then rinsed in phosphate-buffered saline (PBS). Primary abs were detected using fluorescein-or rhodamine-labelled mouse secondary antibodies (Santa Cruz Biotech). Low power photomicrographs were taken on a Zeiss Ultraphot fluorescence microscope.
Tumor microvascularization
Two methods were used to quantify tumor vascularization from immunostained 
Reagents and sources
BD-IX rats were supplied by the Gray Laboratory, Mount Vernon Hospital. L-NAME and AG were purchased from Sigma Ltd., 1400W was synthesized by Dr Malcolm Stewart (University of St Andrews) and AMD compounds were synthesized by Dr Beth Cameron (AnorMED Inc., British Columbia) as in (31) .
Statistical analyses
Power analysis was used to estimate the sample size (n) required to reliably detect a 10 for control and treated groups (n 1 = n 2 ) would detect an effect size of 25% with a statistical power of 0.8 (= 1-β). Some experiments called for unequal sample sizes, namely when comparing tumor growth rates for control groups of animals with treated groups in which some animals were sacrificed while others were allowed to recover.
Unequal samples of n 1 = 16 and n 2 = 10 would allow an effect size of +/-25% to be detected with a statistical power of 0.85.
Data sets were analyzed (GraphPad Prism software) by 2-factor ANOVA, controlled for multiple comparisons, to determine whether differences between growth curves (treated vs control animals) were significant. Student's unpaired t-test was used to determine the significance of differences in Chalkley scores. P values of <0.05 were considered significant. 
RESULTS
Tumor growth curves
All growth curves show mean tumor volumes (+/-SEM) versus time, where n = (number of tumors per rat) x (number of rats in each group). Tumor volumes increased in a near linear fashion while animals were being treated and also afterwards during the recovery period. The slopes of the regression lines are used to compare treated vs control growth rates, expressed throughout as mm 3 /day.
The non-selective NOS inhibitor L-NAME impairs tumor growth.
Tumors grew more slowly on animals treated with L-NAME when compared with control (untreated) animals. This effect was reversed when treatment was withdrawn and animals were given water only. Figure 2 shows results from an experiment in which 18 rats were divided into three groups of 6 (n = 24 tumors, 6 rats per group): group 1 served as controls (curve 1); group 2 received L-NAME (3 mg/ml) from day +15 to day +35 (curve 2); and group 3 received L-NAME from day +10 until day +28, at which time treatment ceased and animals were maintained for a further 7 days before being sacrificed (curve 3). Figure 2B ; 2-factor ANOVA, p< 0.001). The subsequent removal of L-NAME from the drinking water in this group on day +28 allowed tumors to resume growing again. Data from a similar, independent experiment, where treatment with L-NAME (1 mg/ml) commenced on day +12 and ceased on day +24 (arrows), are presented in Figure 2D . Again, growth was retarded during treatment (2-factor ANOVA., p <0.05; n = 12 tumors, 3 rats) and resumed promptly after treatment ceased.
The efficacy of L-NAME depended upon the time at which treatment commenced relative to the time of implantation (day 0). In an independent experiment (not illustrated), one group of animals served as controls (n = 16 tumors, 4 rats), while the other two were treated with L-NAME (1 mg/ml) commencing on day -7 or on day +12.
Again, the growth of tumors on animals treated from day +12 was impaired relative to that of controls (2-factor ANOVA; p< 0.05; n = 12 tumors, 3 rats). However, tumors on animals treated with L-NAME from day -7 grew at a rate that was not significantly different from that of control tumors (2-factor ANOVA; p = 0.61; n = 16 tumors, 4 rats).
In contrast, the ability of L-NAME to impede tumor growth was enhanced when treatment commenced at even later times. Thus, treatment that began on day +20 halted tumor growth completely ( Figure 2C ; curve 4; n = 16 tumors, 4 rats).
Finally, the decrease in tumor growth rates showed only a small dependence on the concentration of L-NAME used. Figure 2C shows data for animals treated with 1 or 6 mg/ml (filled squares; empty diamonds, respectively), commencing on day 10 (n = 24 
13 tumors, 6 rats). Growth retardation is near maximal at the lowest dose (i.e.1 mg/ml).
NOS II selective inhibitors have no effect on tumor growth
The results obtained with AG and 1400W differ markedly from those obtained with L-NAME. Figure 3A shows that tumor growth was unaffected by AG (1mg/ml), In striking contrast to the results obtained with L-NAME and both NO scavengers, treatment with either AG or 1400W had no effect on tumor MVDs (Figure 6 ).
Tumor recovery following treatment with L-NAME or Ru scavenger
Tumors resumed growing when treatments with L-NAME or Ru scavengers were discontinued. The mean rate of growth during recovery from L-NAME increased from 114 +/-7 mm The delay between discontinuing treatment with L-NAME or Ru scavengers and establishing these new rates of growth was remarkably short. Figure 7 illustrates results from three independent studies in which animals were allowed to recover after L-NAME 
DISCUSSION
The ability of L-NAME to suppress tumor growth implies that NO facilitates tumor development (18) . This view would be corroborated if alternative means of depleting NO also curbed tumor growth. We therefore studied the effects of two Ru-based NO scavengers, AMD6221 and AMD6245, on the growth and vascular morphology of the rat P22 carcinosarcoma, comparing their efficacies with those of L-NAME and two NOS II-selective inhibitors, AG and 1400W.
Effects of L-NAME and NO scavengers on tumor growth and vascularization
Treatment with L-NAME ( Figure 2 ) or with NO scavengers (Figure 4 ) retarded tumor growth and decreased MVDs (Figure 5,6 ). The effects of AMD6245 ( Figure 4A) resembled those seen with L-NAME most closely: tumor growth rates were reduced by the same amount (~70%) and both treatments were associated with large decreases in tumor MVDs (Figure 6 ). Tumors quickly began to grow again when treatment with L-NAME or NO scavengers was suspended. The experiments with AMD6221 and AMD6245 showed that renewed growth during the recovery period was accompanied by an increase in tumor MVDs.
Quantitatively, AMD6245 was more effective than AMD6221 at retarding tumor growth and decreasing MVDs. There were other notable differences too, in the way tumors 
responded after withdrawing treatment. Specifically, MVDs were fully restored during recovery from AMD6221 but only partially so after AMD6245; and the rate of tumor regrowth was greater for AMD6221 than for AMD6245.
These observations accord with kinetic studies, showing that the rate constant for the reaction of NO with AMD6245 is much greater (>10 3 fold) than for AMD6221, and with pharmacological measurements showing that the clearance rate for AMD6221 is ~ 20x greater than for AMD6245 (29, 30). The latter result may help explain why
MVDs were reinstated fully during recovery from AMD6221, but only in part after withholding AMD6245 ( Figure 6 ). The recovery period (7 days) was time enough for
MVDs to recover fully from AMD6221, but tumors treated with AMD6245 may have required longer. The effect of prolonging the recovery period was not tested and therefore we cannot exclude the possibility that AMD6245 has other adverse effects on tumor growth that are not shared by AMD6221.
NOS II selective inhibitors have no effect on tumor growth or MVDs
AG and 1400W had no effect on tumor growth (Figure 3 ) or vascularization ( Figure   6 ). This was an unexpected result because Western blots (not illustrated) identified NOS II (as well as NOS III) in tumor extracts. It could be explained however if the dose used (1 mg/ml) was insufficient to inhibit NOS II in vivo, or alternatively, if both compounds were degraded en route to the tumor, either in the gut and/or blood stream. AG retains its ability to inhibit NOS II when given orally at doses (0.5-2.0 mg/ml) comparable with the one used here (40) (41) (42) and both compounds remain 
active when administered by i.v. infusion or bolus injection (26) , so neither explanation seems likely. Instead, the failure of AG and 1400W to influence tumor growth raises the intriguing possibility that NOS III may be a more important source of NO than NOS II in this particular model.
An anti-vascular mechanism for the growth-retarding effects of L-NAME and Ru scavengers
Three of the compounds tested (L-NAME, AMD6221, AMD6245) impaired tumor growth and simultaneously reduced MVDs, while the remaining two (AG, 1400W) had no effect on either. This correlation implies causality and suggests the following mechanism whereby NO could influence tumor development.
Tumor 'feeder' vessels are much less responsive to vasoconstrictors than normal vessels (18), due to increased NO synthesis following induction of the NOS-II ('highoutput') isoform, therefore they are normally highly dilated, a condition that facilitates tumor perfusion. Treatments that lower NO will restore their sensitivity and cause them to constrict, reducing the amount of blood entering the tumor. Since This hypothesis is supported by studies on the effects of NOS inhibitors on tumor perfusion. L-NMMA reduced blood flow in a rat mammary carcinoma (43) while L-NAME decreased vessel diameter in a human tumor xenograft (9) and a rat glioma (44) . L-NNA decreased blood flow in the P22 tumor, by as much as 55%, and increased vascular resistance > 3 fold (19) . Interestingly, a recent study (45) , also using the P22 model, reported that AG and 1400W had no effect on tumor perfusion. This is an important result because it suggests that NO must be severely depleted to reduce tumor perfusion sufficiently to check tumor growth, and that this can be achieved using L-NAME or NO scavengers, but not by selective blockade of NOS-II alone.
The 'anti-vascular' mechanism outlined above arises from our observation that growth retardation is invariably associated with reduced MVDs. This does not preclude an anti-angiogenic effect however, because this would present a similar histological picture. We consider this to be unlikely for the following reasons. First, neither L-NAME nor NO scavengers affected tumor growth when treatment was brought forward (day -7) to encompass the early stages of tumorigenesis, that is, when an anti-angiogenic effect would be most disruptive. Instead, treatment was effective only when initiated several days after implantation, and was most effective when tumors were well-established and of large size ( Figure 2C ). Second, it is unlikely that a well- taken to establish new steady-state rates of growth (ca 1 day) after discontinuing treatment. However, re-inflating a pre-existing but collapsed vasculature, by dilating tumor 'feeder' vessels, could quickly restore the oxygen and nutrients required for growth to resume.
In conclusion, this study shows that NO deprivation per se suppresses tumor growth, for control tumors. Addition of L-NAME (3 mg/ml) to the drinking water on day +15 to animals of group 2 (curve 2) resulted in a marked decrease (~ 70%) in tumor growth rates. N = 24 tumors, 6 rats for curves 1 and 2. B. A similar reduction in growth rate (~67%) was seen in animals of group 3 when treatment commenced on day +10 and was halted on day +28. Tumor growth increased on removing L-NAME from the drinking water (day +28; curve 3). N = 24 tumors, 6 rats for curve 3. C.
Effect of L-NAME showed a small dependence on concentration administered: filled squares, 1 mg/ml; empty diamonds, 6 mg/ml (n = 24 tumors, 6 rats). Addition of L-NAME (10 mg/ml) on day +20 (curve 4; filled triangles) halted tumor growth altogether (n = 16 tumors, 4 rats). D. Results from an experiment in which L-NAME treatment (1 mg/ml) began on day +12 (left arrow) and was withdrawn on day +24 
